Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,762 USD | -0,98% | -13,18% | -25,00% |
28/03 | XERIS BIOPHARMA HOLDINGS, INC. : Oppenheimer verhoogt advies van Neutraal naar Kopen | ZM |
06/03 | Transcript : Xeris Biopharma Holdings, Inc., Q4 2023 Earnings Call, Mar 06, 2024 |
Omzet 2024 * | 184 mln. 173 mln. | Omzet 2025 * | 219 mln. 206 mln. | Marktkapitalisatie | 247 mln. 232 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -55 mln. -51,65 mln. | Nettowinst (verlies) 2025 * | -27 mln. -25,36 mln. | EV/omzet 2024 * | 1,34 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,13 x |
K/w-verhouding 2024 * |
-4,57
x | K/w-verhouding 2025 * |
-9,6
x | Werknemers | 377 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,05% |
Recentste transcriptie over Xeris Biopharma Holdings, Inc.
1 dag | -0,98% | ||
1 week | -13,18% | ||
Lopende maand | -20,25% | ||
1 maand | -17,25% | ||
3 maanden | -28,93% | ||
6 maanden | -0,42% | ||
Lopend jaar | -25,00% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 60 | 01-01-05 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 05-10-21 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 01-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 05-10-21 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 05-10-21 |
Marla Persky
BRD | Director/Board Member | 68 | 05-10-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.00% | 9 M€ | +4,47% | - | |
0.00% | 147 M€ | +4,24% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
18-04-24 | 1,76 | -1,12% | 1 086 061 |
17-04-24 | 1,78 | -1,11% | 1 521 288 |
16-04-24 | 1,8 | -2,70% | 1 836 672 |
15-04-24 | 1,85 | -3,14% | 1 773 740 |
12-04-24 | 1,91 | -5,91% | 2 080 071 |
uitgestelde koers Nasdaq, 18 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-25,00% | 247 mln. | |
+27,97% | 672 mld. | |
+23,82% | 550 mld. | |
-7,02% | 351 mld. | |
+14,85% | 317 mld. | |
+6,25% | 292 mld. | |
+2,81% | 211 mld. | |
-0,70% | 203 mld. | |
-10,14% | 194 mld. | |
-11,81% | 144 mld. |